Kothari Mihir, Rathod Vivek
Department of Pediatric Refractive Services, Jyotirmay Eye Clinic for Children and Adult Squint and Ocular Motility Laboratory, Thane; Department of Pediatric Ophthalmology, Mahatme Eye Hospital, Nagpur, Maharashtra, India.
Department of Pediatric Refractive Services, Jyotirmay Eye Clinic for Children and Adult Squint and Ocular Motility Laboratory, Thane, Maharashtra, India.
Indian J Ophthalmol. 2017 Nov;65(11):1178-1181. doi: 10.4103/ijo.IJO_418_17.
The aim of this study is to assess the efficacy of 1% atropine eye drops for the retardation of progressive axial myopia in Indian eyes.
This prospective interventional cohort study included children aged 5-16 years. Both the eyes of myopic children with progressive increase of ≥-0.5D sphere/year with the best-corrected vision of ≥6/6 were treated with once a day application of 1% atropine eye drops and progressive addition photogray lenses. The progression of myopia after 1-year follow-up was analyzed.
Sixty eyes of thirty myopes were included in the study. The mean age was 10 years and 15 were girls. The mean baseline sphere was -5.2D (-2.5D--13D). Mean duration of follow-up was 23 months (12-36 months). The baseline rate of progression was reduced from -0.6D/year (range -0.5D/year to -3D/year) to -0.2D/year (range 0D/year to -1.5D/year) after atropine therapy. Seventeen patients (57%) had to use the atropine in the daytime to reach the target progression of P = 0.6). The efficacy of atropine drops did not have a correlation with the age of the patients or the magnitude of baseline myopia (Pearson's r = 0).
1% atropine eye drops was well tolerated and efficacious for the retardation of progressive myopia in Indian eyes. Effectiveness was better with daytime application. Further studies are necessary to assess the role of 1% atropine in the rapid progressors and patients poorly responding to low-dose atropine.
本研究旨在评估1%阿托品滴眼液对延缓印度人眼睛轴向进行性近视的疗效。
这项前瞻性干预队列研究纳入了5至16岁的儿童。双眼近视且每年球镜度数进展≥ -0.5D、最佳矫正视力≥6/6的儿童，每天使用一次1%阿托品滴眼液，并佩戴渐进多焦点光致变色镜片进行治疗。对随访1年后的近视进展情况进行分析。
该研究纳入了30名近视患者的60只眼睛。平均年龄为10岁，其中15名是女孩。平均基线球镜度数为-5.2D（-2.5D至-13D）。平均随访时间为23个月（12至36个月）。阿托品治疗后，基线进展率从每年-0.6D（范围为每年-0.5D至-3D）降至每年-0.2D（范围为每年0D至-1.5D）。17名患者（57%）必须在白天使用阿托品才能达到目标进展（P = 0.6）。阿托品滴眼液的疗效与患者年龄或基线近视度数无关（Pearson相关系数r = 0）。
1%阿托品滴眼液耐受性良好，对延缓印度人眼睛的进行性近视有效。白天使用效果更佳。有必要进一步研究评估1%阿托品在快速进展者和对低剂量阿托品反应不佳的患者中的作用。
